| __timestamp | Arrowhead Pharmaceuticals, Inc. | Novavax, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 24419536 | 19928000 |
| Thursday, January 1, 2015 | 34718089 | 30842000 |
| Friday, January 1, 2016 | 40998209 | 46527000 |
| Sunday, January 1, 2017 | 32022880 | 34451000 |
| Monday, January 1, 2018 | 19110051 | 34409000 |
| Tuesday, January 1, 2019 | 26556257 | 34417000 |
| Wednesday, January 1, 2020 | 52275890 | 145290000 |
| Friday, January 1, 2021 | 80981000 | 298358000 |
| Saturday, January 1, 2022 | 124431000 | 488691000 |
| Sunday, January 1, 2023 | 90932000 | 468946000 |
| Monday, January 1, 2024 | 98761000 |
Unleashing insights
In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for financial health. Arrowhead Pharmaceuticals, Inc. and Novavax, Inc. have taken different paths in this regard over the past decade. From 2014 to 2023, Arrowhead's SG&A expenses grew by approximately 300%, peaking in 2022. Meanwhile, Novavax saw a staggering increase of over 2300% during the same period, with a notable surge in 2021 and 2022.
Arrowhead's expenses remained relatively stable until 2020, after which they nearly doubled by 2022. In contrast, Novavax's costs skyrocketed, particularly in 2021, reflecting its aggressive expansion and vaccine development efforts. However, data for 2024 is missing for Novavax, leaving room for speculation on its future strategy.
Understanding these trends offers valuable insights into how these companies navigate financial challenges in a rapidly evolving industry.
Comparing SG&A Expenses: Genmab A/S vs Arrowhead Pharmaceuticals, Inc. Trends and Insights
Comparing SG&A Expenses: Exelixis, Inc. vs Novavax, Inc. Trends and Insights
Operational Costs Compared: SG&A Analysis of Halozyme Therapeutics, Inc. and Arrowhead Pharmaceuticals, Inc.
Lantheus Holdings, Inc. and Novavax, Inc.: SG&A Spending Patterns Compared
Comparing SG&A Expenses: Alkermes plc vs Arrowhead Pharmaceuticals, Inc. Trends and Insights
Breaking Down SG&A Expenses: Ultragenyx Pharmaceutical Inc. vs Arrowhead Pharmaceuticals, Inc.
Operational Costs Compared: SG&A Analysis of Arrowhead Pharmaceuticals, Inc. and Mesoblast Limited
Arrowhead Pharmaceuticals, Inc. and Geron Corporation: SG&A Spending Patterns Compared
Arrowhead Pharmaceuticals, Inc. vs Celldex Therapeutics, Inc.: SG&A Expense Trends
Cost Management Insights: SG&A Expenses for Arrowhead Pharmaceuticals, Inc. and Evotec SE
Breaking Down SG&A Expenses: Ligand Pharmaceuticals Incorporated vs Novavax, Inc.
MannKind Corporation and Novavax, Inc.: SG&A Spending Patterns Compared